Received Jun 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | FY293 | — |
Administration after Below temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a male patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number FY293) for prophylaxis. On 22-MAY-2026, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Administration after Below temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-JUN-2026 Reporter reported an excursion for Boostrix on 11-MAY-2026 with minimum temperature of 30 degree F and that the patient received the vaccine after the excursion and was asking if the patient needs to be revaccinated. This case is one the multiple linked cases reported by the same reporter.; Sender's Comments: US-GSK-US2026074480:SAME REPORTER US-GSK-US2026074486: US-GSK-US2026074479: US-GSK-US2026074483:SAME REPORTER US-GSK-US2026074484:SAME REPORTER US-GSK-US2026074481:SAME REPORTER US-GSK-US2026074485: US-GSK-US2026074478:SAME REPORTER US-GSK-US2026074706:SAME REPORTER